San Francisco biotech company FibroGen guts staff after failed cancer trials
-----
FibroGen, a biotech company focused on cancer research, is laying off 127 workers in San Francisco after flunking two late-stage trials for pancreatic cancer treatment. The cuts add to a wave of biotech layoffs in the Bay Area.The company announced the trial results in a July 30 news release, along with its plan to cut costs: FibroGen is shutting down development of pamrevlumab, the antibody it was testing, and laying off around 75% of its United States workers.
The layoffs will
